Plenary session, April 9th

 

Plenary session, April 9th, Palais de l’Europe, Menton

Presentations are available for viewing in PDF format but should not be used without authors’ permission

08.00 – Forewords (general): M. Meignan – A. Gallamini – C. Haioun 

08.30 – 09.30: New frontiers

Chairmen: A. Levis, L. Giovanella

08.30 – 09.00: L. Kostakoglu

      • Has the interim PET retained its prognostic role in lymphoma? 

09.00 – 09.30: Y. Kasamon

      • How can we incorporate PET in clinical prospective trials (USA experience)? 

09.30 – 11.45: Current studies with interim PET – Hodgkin lymphoma

Chairmen: A. Polliack, A. Biggi
Chairmen: N. Mounier, S. Bardet

09.30 – 10.00: Early HL

      • M. André, J. Raemaekers, A. Versari: The H10 study 
      • J. Radford: The RAPID study 

10.00 – 10.15: Coffee break

10.15 – 11.45: Advanced-stage HL

      • P. Johnson: The RATHL study 
      • A. Gallamini: The GITIL HD0607 study 
      • E. Brusamolino: The IIL HD0801 study 
      • L. Chavdarova: Euronet Paediatric PHL-C1study 
      • O. Casasnovas, C. Fermé: The GELA study 
      • A. Engert: The GHSG HD18 study 
      • E. Dann: The Haifa study 
      • J.M. Zaucha: The Polish study 

12.00 – 12.45: Round table
Is time for a European PET response-adapted protocol for DLBCL?

Chairmen: B. Coiffier (GELA), C. Haioun (GELA)

U. Vitolo (IIL)  , M. Pfreundschuh (DNHLSG), G. Mikhaeel (MRC) , C. Haioun (GELA) 

13.00 – 14.00: Coffee break

14.00 – 15.00: Open issues in interim PET

Chairmen: M. Federico, S. Barrington

14.00 – 14.30: L. Brepoels

      • Interim PET (what can we learn from animal studies?) with emphasis on the effect of drugs 

14.30 – 15.00: R. Hicks

      • Interim PET in solid tumours 

15.00 – 15.10: Coffee break

15.10 – 16.30: Current studies with interim PET – Non Hodgkin lymphoma

Chairmen: H. Tilly, T. van der Borght

Part 1: DLBCL

      • C. Moskowitz: The MSKCC 01-142 study 
      • U. Dührsen: The PETAL study 
      • D. Caballero: The GELTAMO study 
      • O. Casasnovas, F. Morschhauser: The LNH07-3B study 
      • G. Mikhaeel: The UK-NCRI study 
      • L. Sehn: The BCCA study 
      • U. Vitolo: The IIL studies 
      • L. Ceriani: The Swiss experience 
      • M. Trneny: The PET-RIMCEB study 

Part 2: Follicular lymphoma

      • B. Cheson: The CALGB study 
      • M. Meignan: The PCR06002 study 

16.30 – 17.30: International Validation Studies

Chairmen: B. Cheson, J. Seymour

16.30 – 16.45: A. Gallamini

      • International validation Study in HL 

16.45 – 17.00: C. Haioun, E. Itti

      • International validation Study in DLBCL 

17.00 – 17.30: Conclusions and next steps: M. Meignan